74 patents currently held
20 more in force are now held by other companies
Held is read from USPTO's recorded assignments; a transfer never recorded there does not appear.
3 more records may belong here and await a decision; they are not counted.
The next term ends in Nov 2026. from the record
Of the 20 now held by other companies, 14 name Eonhf Inc. as their current owner, and 6 more name another party. Each row says which.
Free plan: 3 watched companies. Pro: unlimited.
Alerts on its grants, lapses and transfers.
44
Ending by 2030
Nov 2026
Next term end
45
Patent families
When these terms end
Held patents by the year their term ends
notable patents
fee due within 90 days
all others
Updated Nov 15, 2026 · includes USPTO assignment & status data published Nov 15, 2026 and grant & fee data published Nov 10, 2026 (weekly) · how we know
Notable: the highest-ranked patents in this portfolio by citations and family size. Fee due within 90 days: a maintenance fee is due within 90 days of when this page was computed and not yet paid.
Notable patents
Ranked by citations and family size, against patents of the same kind granted the same year. How we rank
Notable
Ends Oct 2028 · High confidence
Also notable
Ends Jul 2030 · High confidence
Also notable
Ends no later than Feb 2027 · Low confidence
Biphenyl Compounds Useful as Muscarinic Receptor Antagonists
US 7,288,657
The most cited patent in this portfolio, cited by 77 later US patents, top 10% of utility patents granted in 2007 in our data. Protection runs to 2028.
Crystalline Freebase Forms of a Biphenyl Compound
US 11,649,209
Cited by 4 later US patents, top 25% of utility patents granted in 2023 in our data. Protection runs to 2030. A terminal disclaimer caps this term to an earlier patent's.
Crystalline Forms of a Biphenyl Compound
US 8,242,137
Cited by 31 later US patents, top 25% of utility patents granted in 2012 in our data, and renewed at 3 of 3 maintenance windows. Protection runs to 2027. A terminal disclaimer is on file and its reference is not resolved, so no cap is applied and the date may move earlier, never later.
Formerly held, still cited
Notable
Ends Dec 2031 · High confidence
Cited by 57 later US patents, top 10% of utility patents granted in 2015 in our data, and renewed at every maintenance window due so far. Protection runs to 2031. A terminal disclaimer caps this term to an earlier patent's.
now held by Eonhf, Inc.
Fee deadlines
Maintenance fees fall due 3.5, 7.5 and 11.5 years after grant. A missed fee ends a patent at the end of the six month grace period that follows, not on the due date.
- 2 fees due Nov 16 to 19, 2026 · next Nov 16
- 2 fees due Dec 2 to 4, 2026 · next Dec 2
- 2 fees due Jan 4 to 18, 2027 · next Jan 4
- 2 fees due Feb 15 to 28, 2027 · next Feb 15
- 1 fee due Mar 22, 2027The maintenance fee for Crystalline Form of a Substituted Thiazolylacetic Acid Triethylamine Salt (US 9,139,542) comes due Mar 22, 2027. Unpaid by Sep 22, 2027, it lapses early.
- 3 fees due Apr 20 to 24, 2027 · next Apr 20
- 1 fee due May 14, 2027The maintenance fee for Pyrimidine Compound as Jak Kinase Inhibitor (US 11,814,377) comes due May 14, 2027. Unpaid by Nov 15, 2027, it lapses early.
- 1 fee due Jul 2, 2027The maintenance fee for Crystalline Freebase Forms of a Biphenyl Compound (US 11,858,898) comes due Jul 2, 2027. Unpaid by Jan 3, 2028, it lapses early.
- 2 fees due Aug 4 to 18, 2027 · next Aug 4
Recent changes
- 3 terms have ended since Aug 17, 2026
What they patent
The 5 largest of its 45 families, grouped by real patent family and labeled by the earliest filing in each. No technology classification is inferred from titles.
| Crystalline Freebase Forms of a Biphenyl Compound | 9 in force | to Aug 2031 |
| 4-[2-(2-Fluorophenoxymethyl)PHENYL]PIPERIDINE Compounds | 8 in force | to Oct 2030 |
| Pyrimidine Compound as Jak Kinase Inhibitor | 7 in force | to Oct 2038 |
| Methods for Treating Chronic Obstructive Pulmonary Disease | 3 in force | to Oct 2039 |
| Crystalline Form of a 4-[2-(2-Fluorophenoxymethyl)PHENYL]PIPERIDINE Compound | 3 in force | to Oct 2030 |
Patents held now
Soonest term end first.
| Patent | Title | Status | Expires | Confidence |
|---|---|---|---|---|
| US 7,329,752 | Carbamate Compounds as 5-HT4 Receptor Agonists held by Theravance Biopharma R&D IP, LLC In force · High confidence | In force | High confidence | |
| US 8,377,965 | Crystalline Forms of a Biphenyl Compound held by Theravance Biopharma R&D IP, LLC In force · Medium confidence | In force | Medium confidence | |
| US 7,479,562 | Biphenyl Compounds Useful as Muscarinic Receptor Antagonists held by Theravance Biopharma R&D IP, LLC In force · High confidence | In force | High confidence | |
| US 7,446,114 | Quinolinone Compounds as 5-HT4 Receptor Agonists held by Theravance Biopharma R&D IP, LLC In force · High confidence | In force | High confidence | |
| US 8,242,137 | Crystalline Forms of a Biphenyl Compound held by Theravance Biopharma R&D IP, LLC In force · Low confidence | In force | Low confidence | |
| US 7,528,253 | Compounds Having BETA2 Adrenergic Receptor Agonist and Muscarinic Receptor Antagonist Activity held by Theravance Biopharma R&D IP, LLC In force · High confidence | In force | High confidence | |
| US 7,569,586 | Compounds Having Beta Adrenergic Receptor Agonist and Muscarinic Receptor Antagonist Activity held by Theravance Biopharma R&D IP, LLC In force · High confidence | In force | High confidence | |
| US 7,566,785 | Amidine Substituted Aryl Aniline Compounds held by Theravance Biopharma R&D IP, LLC In force · High confidence | In force | High confidence | |
| US 7,560,469 | Biphenyl Compounds Useful as Muscarinic Receptor Antagonists held by Theravance Biopharma R&D IP, LLC In force · Medium confidence | In force | Medium confidence | |
| US 7,569,588 | Biphenyl Compounds Useful as Muscarinic Receptor Antagonists held by Theravance Biopharma R&D IP, LLC In force · Medium confidence | In force | Medium confidence |
Also on record, not counted in the 74: 20 patents in force now held by others · 158 patents ended · 5 applications pending · 21 applications abandoned. List them
Sources and methods
Compiled from USPTO application file histories, grants and recorded assignments, with the company's own names reviewed by hand. How this record was built
Portfolio grouped automatically from ownership conveyances to the names matched to this company, usually every name that begins with its own, so it counts patents an affiliate holds; each list row names the holder of record. Security interests are excluded and ambiguous records are not reviewed by hand.
Fee due within 90 days marks a patent with a maintenance fee due within 90 days of the date this page was computed and not yet recorded paid, so it can end earlier than the bar shows. A fee left unpaid ends the patent at the close of the six month grace period that follows its due date, not on the due date itself. It is not a prediction that the fee will be missed.
Computed patent terms end on the dates shown. Related patents and pending applications may cover overlapping subject matter.